First Clinical Trial Of Marijuana For Cancer Pain Entering Phase III

Medical cannabis has gained widespread acceptance throughout North America, but many physicians are still hesitant to prescribe the drug without evidence from clinical trials. While many companies are developing synthetic drugs based on cannabinoids, there are some companies that remain committed to realizing the synergistic capabilities of the whole cannabis plant and proving its therapeutic benefit.

In this article, we will look at Tetra Bio-Pharma Inc. (CSE: TBP) (OTCQB: TBPMF) and its recent progress in bringing its smokable marijuana therapeutic to market.

Smokeable Cannabis Trial

Tetra Bio-Pharma’s PPP001 is the first smokeable cannabis drug product being developed for the treatment of pain in late-stage cancer patients. According to Global Pain Management, approximately 50% of cancer patients suffer from pain and more than 600,000 of these patients suffer from moderate-to-severe pain. The overall market for pain-related therapeutics is valued at over $5 billion with over four million cancer patients in the United States alone.